시장보고서

상품코드

1858580

연속 혈당 모니터링 기기(CGMD) 시장 규모와 예측(2021-2031년), 세계 및 지역 점유율, 동향, 성장 기회 분석 : 제품별, 용도별, 검사 부위별, 최종 사용자별, 지역별

Continuous Glucose Monitoring Device Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Product, Application, Testing Sites, End User, and Geography

발행일: 2025년 08월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 275 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

연속 혈당 모니터링 기기(CGMD) 시장은 2024년 127억 1,000만 달러로 평가되었고, 2031년 332억 1,000만 달러에 달할 전망입니다. 시장 성장을 주도하는 주요 요인으로는 전 세계적으로 증가하는 당뇨병 유병률, CGM 기기의 기술 발전, 기존 혈당 모니터링 대비 장점 등이 지속적 혈당 모니터링 기기(CGMD) 채택을 촉진하고 있습니다. 또한 인슐린 투여 시스템과의 통합 및 인공지능 기반 의사 결정 지원 기능이 예측 기간 동안 시장을 주도할 것으로 보입니다. 그러나 높은 비용, 제한된 보험 적용 범위, 사용자 편의성 및 착용성 문제 등이 시장 성장의 걸림돌로 작용할 전망입니다.

연속 혈당 모니터링(CGM) 기기는 기존의 혈당 측정 방식에 비해 상당하고 임상적으로 의미 있는 이점을 제공하여 전 세계 수백만 명의 당뇨병 관리를 근본적으로 변화시키고 있습니다. 주기적인 손가락 채혈 검사에 의존하는 기존 방식과 달리, CGM은 최소 침습적 센서를 통해 포도당 수치를 실시간으로 지속적으로 측정하여 사용자와 의료진이 단일 데이터 포인트가 아닌 포도당 변동성과 추세를 평가할 수 있게 합니다. 최근 임상 연구에 따르면 CGM 사용은 HbA1c 수치를 0.25%에서 3.0%까지 감소시키고 “목표 범위 내 시간”(혈당이 목표 수준을 유지하는 시간 비율)을 15-34% 향상시키며, 이 두 가지 모두 당뇨병 합병증 위험 감소 및 장기적 결과 개선과 연관됩니다.

CGM 기술의 가장 영향력 있는 발전 중 하나는 저혈당 및 고혈당에 대한 실시간 경보 기능입니다. 이러한 경보는 즉각적인 개입(예 : 신속한 탄수화물 섭취 또는 인슐린 용량 조정)을 가능하게 하여 위험한 증상의 빈도와 심각성을 획기적으로 감소시킵니다. 연구에 따르면 최신 CGM에 통합된 저혈당 예측 알고리즘은 경고 기능이 없는 경우 대비 최대 92%, 표준 경고 대비 47%까지 목표 범위 미만 시간을 감소시켜, 특히 수면 중이나 저혈당 고위험군 환자의 안전성을 크게 향상시킵니다. 또한 야간 저혈당 예측 기술은 안전한 혈당 기준치 미만 상태로 보내는 야간 시간을 37% 감소시켜 취약한 시간대에 상당한 보호 효과를 제공합니다.

CGM은 식이 섭취, 신체 활동, 약물 반응, 스트레스 요인을 해당 혈당 변동과 연결하여 개인 맞춤형 생활 습관 변화를 유도하는 혁신적인 교육 도구입니다. 이러한 지속적인 시각적 피드백은 즉각적이고 개인화된 생리학적 데이터가 부족한 기존 교육 방법보다 훨씬 우수한 통찰력을 제공함으로써 자가 관리 능력과 환자 참여도를 향상시킵니다. 이러한 지속적인 데이터 흐름은 동적 당뇨병 관리를 가능하게 하여 환자와 의료진이 사전 예방적이며 근거 기반의 결정을 내리고, 진료 방문 사이에도 치료를 조정하며, 식후 혈당 급상승이나 야간 고혈당과 같이 이전에는 인지하지 못했던 패턴을 인식할 수 있게 합니다.

CGM은 또한 의료진에게 목표 범위 내 시간, 저혈당/고혈당 빈도, 혈당 변동성 등의 지표를 포함한 상세하고 포괄적인 혈당 프로필을 제공합니다. 이를 통해 치료 강도 조절, 위험 계층화, 예방 전략을 더욱 정밀하게 수행하여 입원률을 낮추고 심각한 합병증을 예방할 수 있습니다. 통합 무선 데이터 전송 및 클라우드 기반 저장소로 강화된 원격 환자 데이터 모니터링 기능은 진료 제공을 효율화하고 치료 순응도를 높입니다. 이는 특히 어린이, 노인, 임산부, 저혈당 인지 장애가 있는 개인 등 취약 계층에게 유익합니다.

CGM은 기존 방식에서 치료 순응도와 삶의 질을 저해했던 빈번한 손가락 채혈의 실질적 및 심리적 부담을 제거합니다. 어린이들은 특히 이 “손가락 찔림 없는” 접근법을 높이 평가하며, 집중 치료를 받는 환자들도 비용 및 기기 복잡성 문제에도 불구하고 더 높은 치료 만족도와 장기적인 기기 유지율을 보고합니다.

CGM은 혈당 조절 통계의 획기적 개선, 저혈당 예방, 실시간 데이터를 통한 환자 역량 강화, 실행 가능한 지표를 통한 의료진 팀의 종합적 지원, 전반적인 삶의 질 향상 등을 포괄합니다. 이러한 임상적으로 검증된 이점으로 인해 국제 당뇨병 치료 기준은 1형 당뇨병에 CGM 사용을 강력히 권고하며 2형 당뇨병에 대한 적응증 확대를 권장합니다. 이는 CGM이 현대 당뇨병 치료의 핵심 기둥으로서의 역할을 강화합니다.

비교기업 분석에서는 제품 포트폴리오(제품 만족도, 제품 기능, 가용성), 최근 시장 동향(합병 및 인수, 신제품 발매 및 강화, 투자 및 자금 조달, 수상, 합의, 제휴 및 협력, 인지, 확대), 경쟁 구도의 보다 좋은 의사결정과 이해를 돕는 지역적 존재에 근거해 세계의 연속 혈당 모니터링 기기(CGMD) 시장에서 주요 공급업체의 최근 중요한 동향과 혁신에 대해 깊이 조사했습니다. 주요 시장 기업은 Abbott Laboratories, Dexcom Inc., Ypsomed Holding AG, Medtronic, F. Hoffmann-La Roche Ltd., Senseonics Holdings Inc., i-SENS Inc., A. Menarini Diagnostics srl, Tandem Diabetes Care, Inc., Medtrum Technologies Inc. 등입니다.

제품 유형별로는 연속 혈당 모니터링 기기(CGMD) 시장이 센서, 송신기, 수신기로 세분화됩니다. 2024년 기준 센서 부문이 시장 점유율 1위를 차지했습니다.

용도별로 시장은 1형 당뇨병과 2형 당뇨병으로 분류됩니다. 2형 당뇨병 부문은 2024년 연속 혈당 모니터링 기기(CGMD) 시장에서 가장 큰 점유율을 차지했습니다.

검사 부위별로는 시장이 손가락 끝 검사(fingertip testing)와 대체 부위 검사(alternate site testing)로 분류됩니다. 2024년 연속 혈당 모니터링 기기(CGMD) 시장에서 손가락 끝 검사 부문이 가장 큰 점유율을 차지했습니다. 지혈당 검사(SMBG)로도 알려진 손가락 끝 혈당 검사는 오랫동안 당뇨병 관리의 기초가 되어 왔습니다. 이는 손가락을 찔러 한 방울의 혈액을 측정기에 떨어뜨려 직접 모세혈관 혈당 수치를 제공합니다. CGM이 연속 데이터와 추세 중심의 데이터로 점차 주류를 이루고 있지만, 지혈당 검사는(일부 CGM) 보정 및 급격한 혈당 변화나 측정 오류가 의심될 때 확인을 위해 여전히 필수적입니다.

정확도는 여전히 SMBG의 장점 중 하나다. 최신 손가락 채혈 측정기는 일반적으로 평균 절대 상대 차이(MARD)가 더 낮으며, 대개 5-6% 범위에 속합니다. 반면 덱스콤 G7이나 프리스타일 리브레 3 같은 최상위 CGM의 MARD는 약 8-9% 수준입니다. 이러한 정확도 우위는 저혈당 확인이나 CGM 보정 등 정확한 혈당 수치가 필요한 상황에서 특히 가치가 있습니다. 지연 시간과 간질액 대 모세혈관액의 차이는 여전히 핵심적인 차이점입니다. CGM은 간질액 포도당을 측정하며, 이는 일반적으로 혈당보다 약 5-15분 정도 지연됩니다. 실제 혈당보다 지연되는 CGM과 달리, 핑거스틱 검사는 진정한 모세혈관 포도당 수치를 즉시 확인할 수 있게 하여 급격한 변화가 발생하거나 기기 경고가 증상과 일치하지 않을 때 매우 유용합니다.

최종 사용자 측면에서 연속 혈당 모니터링 기기(CGMD) 시장은 병원 및 클리닉, 자가 또는 가정 관리로 구분됩니다. 자가 또는 가정 관리 부문은 2024년 연속 혈당 모니터링 기기(CGMD) 시장에서 가장 큰 점유율을 차지했습니다.

연속 혈당 모니터링 기기(CGMD) 시장에서 활동하는 기업들은 다양한 유기적 및 비유기적 전략을 채택합니다. 유기적 전략은 주로 제품 출시 및 제품 승인을 포함합니다. 시장에서 목격된 비유기적 성장 전략은 인수, 협력 및 파트너십입니다. 이러한 성장 전략을 통해 시장 참여자들은 사업을 확장하고 지리적 입지를 강화하며 전체 시장 성장에 기여할 수 있습니다. 또한 인수 및 파트너십은 고객 기반을 강화하고 제품 포트폴리오를 확장하는 데 도움이 되었습니다. 주요 연속 혈당 모니터링 기기(CGMD) 시장 참여자들의 몇 가지 중요한 발전 사항은 아래에 나열되어 있습니다.

2025년 7월, Abbott는 2개의 새로운 매장용(OTC) 연속 혈당 모니터링 시스템인 Lingo와 Libre Rio의 FDA 승인을 받았습니다. 이들은 FreeStyle Libre의 기술을 기반으로 하며 기존의 당뇨병 관리뿐만 아니라 일반적인 건강과 웰빙까지 혈당 모니터링에 대한 액세스를 확대합니다. 이것은 IoT 의료기기의 소비자화를 향한 큰 단계입니다.

2025년 7월, 덱스컴은 미국 최초로 FDA 인증 1을 받은 시중에서 판매되는 혈당 바이오센서인 스텔로에 AI를 활용한 새로운 사진에 의한 식기록 기능을 출시했다고 발표했습니다. Dexcom의 스마트 다이어트 기록 기능은 사용자가 더 일관되게 다이어트를 기록하도록 권장하고 가능하게 합니다. Stelo와 Dexcom G7 사용자는 앱에서 식사 사진을 찍을 수 있으며 AI가 자동으로 재료를 식별하고 식사 설명을 입력합니다. Dexcom G7은 미국에서 유일하게 사진 로깅을 지원하는 처방 연속 혈당 모니터입니다.

2025년 4월, 덱스컴은 미국에서 18세 이상의 당뇨병 환자를 대상으로 한 덱스콤 G7 15일간 연속 혈당 모니터링 시스템을 FDA가 승인했다고 발표했습니다. Dexcom G7 15 Day는 MARD8.0%로 임상적으로 A1C 저하, 고혈당 및 저혈당 감소, 범위 내 시간 연장이 입증된 Dexcom CGM의 성능을 기반으로 합니다.

연속 혈당 모니터링 기기(CGMD) 시장 : 주요 시장 역학
시장 성장 촉진요인
- 전 세계 당뇨병 유병률 증가
- CGM 기기의 기술 발전
- 기존 혈당 모니터링 대비 장점
시장 성장 억제요인
- 높은 비용 및 제한된 보험 적용
- 사용자 편의성 및 착용성 문제
시장 기회
- 신흥 시장 및 미개척 시장의 접근성 향상
향후의 동향
- 인슐린 투여 시스템과의 통합 및 인공지능 기반 의사 결정 지원
성장 촉진요인과 억제요인의 영향

제6장 연속 혈당 모니터링 기기(CGMD) 시장 : 세계 시장 분석

연속 혈당 모니터링 기기(CGMD) 시장 수익(2021-2031년)
연속 혈당 모니터링 기기(CGMD) 시장 예측 분석

제7장 연속 혈당 모니터링 기기(CGMD) 시장 분석 : 제품별

센서
송신기
수신기

제8장 연속 혈당 모니터링 기기(CGMD) 시장 분석 : 용도별

1형 당뇨병
2형 당뇨병

제9장 연속 혈당 모니터링 기기(CGMD) 시장 분석 : 검사 부위별

손가락 끝 검사
대체 부위 검사

제10장 연속 혈당 모니터링 기기(CGMD) 시장 분석 : 최종 사용자별

병원 및 진료소
셀프케어 또는 홈케어

제11장 연속 혈당 모니터링 기기(CGMD) 시장 분석 : 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 인도
- 일본
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제12장 경쟁 구도

주요 기업의 히트맵 분석
기업의 포지셔닝과 집중도

제13장 세계의 연속 혈당 모니터링 기기 시장 상황

제품 출시, 제품 승인
사업 확대 및 기타 전략적 전개

제14장 기업 프로파일

Abbott Laboratories
Dexcom Inc
Ypsomed Holding AG
Medtronic Plc
F. Hoffmann-La Roche Ltd
Senseonics Holdings Inc
i-SENS Inc
A. Menarini Diagnostics srl
Tandem Diabetes Care Inc
Medtrum Technologies Inc.

제15장 부록

HBR 25.11.27

The continuous glucose monitoring device (CGMD) market is projected to reach US$33.21 billion by 2031 from US$12.71 billion in 2024. The market is estimated to register a CAGR of 14.9% during 2025-2031. Major factors driving the market growth include a rising global prevalence of diabetes, technological advancements in CGM devices, and benefits over conventional glucose monitoring are propelling the adoption of continuous glucose monitoring device (CGMD). Further, integration with insulin delivery and AI-driven decision support will likely boost the market during the forecast period. However, the high cost and limited reimbursement and user comfort and wearability challenges are among the market deterrents.

Continuous glucose monitoring (CGM) devices offer substantial and clinically meaningful advantages over conventional blood glucose monitoring methods, fundamentally transforming diabetes management for millions worldwide. Unlike traditional approaches that rely on periodic finger-prick tests, CGMs provide real-time, continuous measurement of glucose levels via minimally invasive sensors, allowing users and clinicians to assess glucose variability and trends rather than single data points. Recent clinical studies report that CGM use achieves reductions in HbA1c levels ranging from 0.25% to 3.0% and improves "time in range" (the percentage of time glucose remains within target levels) by 15-34%, both of which are associated with lower risk of diabetes complications and improved long-term outcomes.

One of the most impactful developments in CGM technology is its ability to deliver real-time alerts for hypoglycemia and hyperglycemia. These alarms enable immediate intervention, such as prompt carbohydrate consumption or insulin dose adjustment, drastically reducing the frequency and severity of dangerous episodes. Studies show that low-glucose prediction algorithms integrated in newer CGMs can reduce time below range by up to 92% compared to no alerts and 47% compared to standard alerts, significantly improving safety, especially during sleep or for patients at high risk of hypoglycemia. Additionally, nocturnal low-glucose prediction technology has demonstrated a 37% reduction in nightly time spent below the safe glucose threshold, providing substantial protection during vulnerable hours.

CGMs are transformational educational tools, motivating personalized lifestyle change by mapping dietary intake, physical activity, medication response, and stress factors to corresponding glucose fluctuations. This ongoing visual feedback enhances self-management skills and patient engagement, offering insights far superior to conventional education methods that lack immediate and personalized physiological data. Such continuous data streams enable dynamic diabetes management, allowing patients and healthcare providers to make proactive, evidence-based decisions, adjust therapy between clinic visits, and recognize previously unnoticed patterns such as postprandial spikes or nocturnal highs.

CGM also delivers a detailed and comprehensive glucose profile for healthcare providers, including metrics such as time in range, hypoglycemia/hyperglycemia frequency, and glycemic variability. This enables more precise treatment intensification, risk stratification, and preventive strategies to lower hospitalization rates and avoid severe complications. The capability to remotely monitor patient data, enhanced by integrated wireless data transmission and cloud-based storage, streamlines care delivery and boosts adherence. This is particularly beneficial for vulnerable groups, including children, the elderly, pregnant women, and individuals with impaired awareness of hypoglycemia.

CGMs eliminate the practical and psychological burden of frequent finger sticks, a limitation that impaired adherence and quality of life with earlier methods. Children particularly value this "finger-prick-free" approach, and patients undergoing intensive therapy report higher treatment satisfaction and long-term device retention rates despite cost and device complexity challenges.

CGM encompasses dramatic improvements in glycemic control statistics, hypoglycemia prevention, patient empowerment through real-time data, holistic healthcare-team support with actionable metrics, and enhanced overall quality of life. With these clinically validated benefits, international diabetes care standards strongly recommend CGM for type 1 diabetes and expanding indications for type 2 diabetes. This reinforces CGM's role as a cornerstone of modern diabetes care.

The comparative company analysis evaluates and categorizes the continuous glucose monitoring device (CGMD) market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global continuous glucose monitoring device (CGMD) market. The key market players are Abbott Laboratories; Dexcom Inc., Ypsomed Holding AG, Medtronic, F. Hoffmann-La Roche Ltd, Senseonics Holdings Inc, i-SENS Inc., A. Menarini Diagnostics s.r.l, Tandem Diabetes Care, Inc., and Medtrum Technologies Inc.

Based on product, the continuous glucose monitoring device (CGMD) market is segmented into sensors, transmitters, and receivers. The sensors segment held the largest share of the market in 2024.

By application, the market is categorized into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment accounted for the largest continuous glucose monitoring device (CGMD) market share in 2024.

By testing sites, the market is categorized into fingertip testing and alternate site testing. The fingertip testing segment accounted for the largest share of the continuous glucose monitoring device (CGMD) market in 2024. Fingertip blood glucose testing, also known as self-monitoring of blood glucose (SMBG), has long been the foundation of diabetes management. It offers direct capillary blood readings by pricking a finger and applying a drop to a meter. Though CGMs increasingly dominate due to their continuous and trend-focused data, finger sticks remain essential for calibration (in some CGMs) and confirmation during rapid glucose changes or suspected measurement errors.

Accuracy remains one of SMBG's advantages. Modern fingerstick meters typically demonstrate lower Mean Absolute Relative Difference (MARD), often in the 5-6% range, compared to around 8-9% for top-tier CGMs such as the Dexcom G7 and FreeStyle Libre 3. This edge in accuracy is particularly valuable in situations requiring precise glucose readings, such as confirming hypoglycemia or calibrating CGMs. Lag time and interstitial vs. capillary fluid differences remain key distinctions. CGMs measure interstitial fluid glucose, which typically lags behind blood glucose by ~5-15 minutes. Behind actual blood glucose, Fingerstick testing provides immediate access to true capillary glucose levels, making it invaluable when rapid changes occur or device alerts seem inconsistent with symptoms.

Regarding end user, the continuous glucose monitoring device (CGMD) market is segmented into hospitals and clinics, and self or homecare. The self or homecare segment held the largest share of the continuous glucose monitoring device (CGMD) market in 2024.

Companies operating in the continuous glucose monitoring device (CGMD) market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key continuous glucose monitoring device (CGMD) market players are listed below.

In July 2025, Abbott obtained FDA approvals for two new over-the-counter (OTC) continuous glucose monitoring systems, Lingo and Libre Rio. These are based on the FreeStyle Libre technology, expanding access to glucose monitoring beyond traditional diabetes management to general health and wellness. This is a major step in consumerizing IoT medical devices.

In July 2025, DexCom, Inc. announced it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the US. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now take a photo of their food in the app, where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the US's only prescription continuous glucose monitors to support photo logging.

In April 2025, DexCom, Inc. announced the FDA has cleared the Dexcom G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Continuous Glucose Monitoring Device (CGMD) Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Continuous Glucose Monitoring Device (CGMD) Market - Key Market Dynamics

5.1 Continuous Glucose Monitoring Device (CGMD) Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Global Prevalence of Diabetes
- 5.2.2 Growing Technological Advancements in CGM Devices
- 5.2.3 Benefits Over Conventional Glucose Monitoring
5.3 Market Restraints
- 5.3.1 High Cost and Limited Reimbursement
- 5.3.2 User Comfort and Wearability Challenges
5.4 Market Opportunities
- 5.4.1 Increasing Accessibility in Emerging and Underserved Markets
5.5 Future Trends
- 5.5.1 Integration with Insulin Delivery and AI-Driven Decision Support
5.6 Impact of Drivers and Restraints:

6. Continuous Glucose Monitoring Device (CGMD) Market - Global Market Analysis

6.1 Continuous Glucose Monitoring Device (CGMD) Market Revenue (US$ Million), 2021-2031
6.2 Continuous Glucose Monitoring Device (CGMD) Market Forecast Analysis

7. Continuous Glucose Monitoring Device (CGMD) Market Analysis - by Product

7.1 Sensors
- 7.1.1 Overview
- 7.1.2 Sensors: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Transmitters
- 7.2.1 Overview
- 7.2.2 Transmitters: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Receivers
- 7.3.1 Overview
- 7.3.2 Receivers: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)

8. Continuous Glucose Monitoring Device (CGMD) Market Analysis - by Application

8.1 Type 1 Diabetes
- 8.1.1 Overview
- 8.1.2 Type 1 Diabetes: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Type 2 Diabetes
- 8.2.1 Overview
- 8.2.2 Type 2 Diabetes: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)

9. Continuous Glucose Monitoring Device (CGMD) Market Analysis - by Testing Sites

9.1 Fingertip Testing
- 9.1.1 Overview
- 9.1.2 Fingertip Testing: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Alternate Site Testing
- 9.2.1 Overview
- 9.2.2 Alternate Site Testing: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)

10. Continuous Glucose Monitoring Device (CGMD) Market Analysis - by End User

10.1 Hospitals and Clinics
- 10.1.1 Overview
- 10.1.2 Hospitals and Clinics: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Self or Homecare
- 10.2.1 Overview
- 10.2.2 Self or Homecare: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast to 2031 (US$ Million)

11. Continuous Glucose Monitoring Device (CGMD) Market - Geographical Analysis

11.1 Overview
11.2 North America
- 11.2.1 North America Continuous Glucose Monitoring Device (CGMD) Market Overview
- 11.2.2 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue, 2021-2031 (US$ Million)
- 11.2.3 North America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
  - 11.2.3.1 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Product
- 11.2.4 North America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
  - 11.2.4.1 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Application
- 11.2.5 North America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
  - 11.2.5.1 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Testing Sites
- 11.2.6 North America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.2.6.1 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by End User
- 11.2.7 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.1 North America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.2 United States: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.2.7.2.1 United States: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.2.7.2.2 United States: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.2.7.2.3 United States: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.2.7.2.4 United States: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.2.7.3 Canada: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.2.7.3.1 Canada: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.2.7.3.2 Canada: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.2.7.3.3 Canada: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.2.7.3.4 Canada: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.2.7.4 Mexico: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.2.7.4.1 Mexico: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.2.7.4.2 Mexico: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.2.7.4.3 Mexico: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.2.7.4.4 Mexico: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
11.3 Europe
- 11.3.1 Europe Continuous Glucose Monitoring Device (CGMD) Market Overview
- 11.3.2 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue, 2021-2031 (US$ Million)
- 11.3.3 Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
  - 11.3.3.1 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Product
- 11.3.4 Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
  - 11.3.4.1 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Application
- 11.3.5 Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
  - 11.3.5.1 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Testing Sites
- 11.3.6 Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.3.6.1 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by End User
- 11.3.7 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.1 Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.2 Germany: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.3.7.2.1 Germany: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.3.7.2.2 Germany: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.3.7.2.3 Germany: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.3.7.2.4 Germany: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.3.7.3 United Kingdom: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.3.7.3.1 United Kingdom: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.3.7.3.2 United Kingdom: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.3.7.3.3 United Kingdom: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.3.7.3.4 United Kingdom: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.3.7.4 France: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.3.7.4.1 France: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.3.7.4.2 France: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.3.7.4.3 France: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.3.7.4.4 France: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.3.7.5 Italy: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.3.7.5.1 Italy: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.3.7.5.2 Italy: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.3.7.5.3 Italy: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.3.7.5.4 Italy: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.3.7.6 Spain: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.3.7.6.1 Spain: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.3.7.6.2 Spain: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.3.7.6.3 Spain: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.3.7.6.4 Spain: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.3.7.7 Rest of Europe: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.3.7.7.1 Rest of Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.3.7.7.2 Rest of Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.3.7.7.3 Rest of Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.3.7.7.4 Rest of Europe: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
11.4 Asia Pacific
- 11.4.1 Asia Pacific Continuous Glucose Monitoring Device (CGMD) Market Overview
- 11.4.2 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue, 2021-2031 (US$ Million)
- 11.4.3 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
  - 11.4.3.1 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Product
- 11.4.4 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
  - 11.4.4.1 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Application
- 11.4.5 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
  - 11.4.5.1 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Testing Sites
- 11.4.6 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.4.6.1 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by End User
- 11.4.7 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.1 Asia Pacific: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.2 China: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.4.7.2.1 China: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.4.7.2.2 China: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.4.7.2.3 China: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.4.7.2.4 China: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.4.7.3 India: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.4.7.3.1 India: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.4.7.3.2 India: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.4.7.3.3 India: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.4.7.3.4 India: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.4.7.4 Japan: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.4.7.4.1 Japan: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.4.7.4.2 Japan: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.4.7.4.3 Japan: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.4.7.4.4 Japan: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.4.7.5 South Korea: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.4.7.5.1 South Korea: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.4.7.5.2 South Korea: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.4.7.5.3 South Korea: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.4.7.5.4 South Korea: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.4.7.6 Australia: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.4.7.6.1 Australia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.4.7.6.2 Australia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.4.7.6.3 Australia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.4.7.6.4 Australia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.4.7.7 Rest of APAC: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.4.7.7.1 Rest of APAC: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.4.7.7.2 Rest of APAC: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.4.7.7.3 Rest of APAC: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.4.7.7.4 Rest of APAC: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
11.5 Middle East and Africa
- 11.5.1 Middle East and Africa Continuous Glucose Monitoring Device (CGMD) Market Overview
- 11.5.2 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue, 2021-2031 (US$ Million)
- 11.5.3 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
  - 11.5.3.1 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Product
- 11.5.4 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
  - 11.5.4.1 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Application
- 11.5.5 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
  - 11.5.5.1 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Testing Sites
- 11.5.6 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.5.6.1 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by End User
- 11.5.7 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.1 Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.2 Saudi Arabia: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.5.7.2.1 Saudi Arabia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.5.7.2.2 Saudi Arabia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.5.7.2.3 Saudi Arabia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.5.7.2.4 Saudi Arabia: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.5.7.3 South Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.5.7.3.1 South Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.5.7.3.2 South Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.5.7.3.3 South Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.5.7.3.4 South Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.5.7.4 United Arab Emirates: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.5.7.4.1 United Arab Emirates: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.5.7.4.2 United Arab Emirates: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.5.7.4.3 United Arab Emirates: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.5.7.4.4 United Arab Emirates: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.5.7.5 Rest of Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.5.7.5.1 Rest of Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.5.7.5.2 Rest of Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.5.7.5.3 Rest of Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.5.7.5.4 Rest of Middle East and Africa: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
11.6 South and Central America
- 11.6.1 South and Central America Continuous Glucose Monitoring Device (CGMD) Market Overview
- 11.6.2 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue, 2021-2031 (US$ Million)
- 11.6.3 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
  - 11.6.3.1 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Product
- 11.6.4 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
  - 11.6.4.1 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Application
- 11.6.5 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
  - 11.6.5.1 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Testing Sites
- 11.6.6 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.6.6.1 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by End User
- 11.6.7 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.1 South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.2 Brazil: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.6.7.2.1 Brazil: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.6.7.2.2 Brazil: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.6.7.2.3 Brazil: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.6.7.2.4 Brazil: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.6.7.3 Argentina: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.6.7.3.1 Argentina: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.6.7.3.2 Argentina: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.6.7.3.3 Argentina: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.6.7.3.4 Argentina: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User
  - 11.6.7.4 Rest of South and Central America: Continuous Glucose Monitoring Device (CGMD) Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.6.7.4.1 Rest of South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Product
    - 11.6.7.4.2 Rest of South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Application
    - 11.6.7.4.3 Rest of South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by Testing Sites
    - 11.6.7.4.4 Rest of South and Central America: Continuous Glucose Monitoring Device (CGMD) Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration

13. Global Continuous Glucose Monitoring Device Market Industry Landscape

13.1 Overview
13.2 Product Launch, Product Approvals
13.3 Expansions And Other Strategic Developments

14. Company Profiles

14.1 Abbott Laboratories
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Dexcom Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Ypsomed Holding AG
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Medtronic Plc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 F. Hoffmann-La Roche Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Senseonics Holdings Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 i-SENS Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 A. Menarini Diagnostics s.r.l
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Tandem Diabetes Care Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Medtrum Technologies Inc.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 List of Abbreviations